In vivo efficacy of humanized exposures of ceftazidime-avibactam in comparison with ceftazidime against contemporary Enterobacteriaceae isolates

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6913-6919

  MacVane, Shawn H ^a   Crandon, Jared L ^a   Nichols, Wright W ^b   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; CEFTAZIDIME; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BETA LACTAMASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIUM ISOLATE; COLONY FORMING UNIT; DRUG EFFICACY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; FEMALE; IN VIVO STUDY; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PROTEUS MIRABILIS; PROVIDENCIA STUARTII; SERRATIA MARCESCENS; ANIMAL; COMPARATIVE STUDY; DRUG EFFECTS; ENTEROBACTERIACEAE INFECTIONS; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; NEUTROPENIA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASE INHIBITORS; CEFTAZIDIME; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84908271938     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03267-14     Document Type: Article

References (29)

1. Lautenbach E, Polk R. 2007. Resistant gram-negative bacilli: a neglected healthcare crisis? Am. J. Health Syst. Pharm. 64(23 Suppl 14):S3-S21. http://dx.doi.org/10.2146/ajhp070477.
2. Cosgrove SE. 2006. The relationship between antimicrobial resistance and patient outcomes: mortality, length of stay, and health care costs. Clin. Infect. Dis. 42(Suppl 2):S82-S89. http://dx.doi.org/10.1086/499406.
3. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf.
4. Kaiser RM, Castanheira M, Jones RN, Tenover F, Lynfield R. 2013. Trends in Klebsiella pneumoniae carbapenemase-positive K. pneumoniae in US hospitals: report from the 2007-2009 SENTRY antimicrobial surveillance program. Diagn. Microbiol. Infect. Dis. 76:356-360. http://dx.doi.org/10.1016/j.diagmicrobio.2013.03.032.
5. Stachyra T, Levasseur P, Pechereau MC, Girard AM, Claudon M, Miossec C, Black MT. 2009. In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J. Antimicrob. Chemother. 64:326-329. http://dx.doi.org/10.1093/jac/dkp197.
6. Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, Woodford N. 2011. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 55:390-394. http://dx.doi.org/10.1128/AAC.00756-10.
7. Lagacé-Wiens PR, Tailor F, Simner P, DeCorby M, Karlowsky JA, Walkty A, Hoban DJ, Zhanel GG. 2011. Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases. Antimicrob. Agents Chemother. 55:2434-2437. http://dx.doi.org/10.1128/AAC.01722-10.
8. Endimiani A, Hujer KM, Hujer AM, Pulse ME, Weiss WJ, Bonomo RA. 2011. Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 55:82-85. http://dx.doi.org/10.1128/AAC.01198-10.
9. Crandon JL, Schuck VJ, Banevicius MA, Beaudoin ME, Nichols WW, Tanudra MA, Nicolau DP. 2012. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidimeavibactam against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 56:6137-6146. http://dx.doi.org/10.1128/AAC.00851-12.
10. Walkty A, DeCorby M, Lagacé-Wiens PR, Karlowsky JA, Hoban DJ, Zhanel GG. 2011. In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). Antimicrob. Agents Chemother. 55:2992-2994. http://dx.doi.org/10.1128/AAC.01696-10.
11. Levasseur P, Girard AM, Claudon M, Goossens H, Black MT, Coleman K, Moissec C. 2012. In vitro antibacterial activity of the ceftazidimeavibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 56:1606-1608. http://dx.doi.org/10.1128/AAC.06064-11.
12. Flamm RK, Stone GG, Sader HS, Jones RN, Nichols WW. Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value. J. Chemother., in press. http://dx.doi.org/10.1179/1973947813Y.0000000145.
13. Clinical Laboratory Standards Institute. 2011. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th ed. CLSI publication M07-A8. Clinical Laboratory Standards Institute, Wayne, PA.
14. Andes D, Craig WA. 1998. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob. Agents Chemother. 42:2375-2379.
15. Tawara S, Matsumoto S, Kamimura T, Goto S. 1992. Effect of protein binding in serum on therapeutic efficacy of cephem antibiotics. Antimicrob. Agents Chemother. 36:17-24. http://dx.doi.org/10.1128/AAC.36.1.17.
16. Drusano GL, Standiford HC, Fitzpatrick B, Leslie J, Tangtatsawasdi P, Ryan P, Tatem B, Moody MR, Schimpff SC. 1984. Comparison of the pharmacokinetics of ceftazidime and moxalactam and their microbiological correlates in volunteers. Antimicrob. Agents Chemother. 26:388-393. http://dx.doi.org/10.1128/AAC.26.3.388.
17. Nicolau DP, Nightingale CH, Banevicius MA, Fu Q, Quintiliani R. 1996. Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections. Antimicrob. Agents Chemother. 40:61-64.
18. Hoaglin DC, Iglewicz B, Tukey JW. 1986. Performance of some resistant rules for outlier labeling. J. Am. Stat. Assoc. 81:991-999. http://dx.doi.org/10.1080/01621459.1986.10478363.
19. Bush K. 2010. Alarming beta-lactamase-mediated resistance in multi-drug-resistant Enterobacteriaceae. Curr. Opin. Microbiol. 13:558-564. http://dx.doi.org/10.1016/j.mib.2010.09.006.
20. Crandon JL, Nicolau DP. 2013. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gramnegative organisms, including metallo-β-lactamase producers. Antimicrob. Agents Chemother. 57:3299-3306. http://dx.doi.org/10.1128/AAC.01989-12.
21. Wiskirchen DE, Crandon JL, Furtado GH, Williams G, Nicolau DP. 2011. In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 55:3220-3225. http://dx.doi.org/10.1128/AAC.00024-11.
22. Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. 2013. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial. J. Antimicrob. Chemother. 68:1183-1192. http://dx.doi.org/10.1093/jac/dks523.
23. Vazquez JA, González Patzán LD, Stricklin D, Duttaroy DD, Kreidly Z, Lipka J, Sable C. 2012. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr. Med. Res. Opin. 28:1921-1931. http://dx.doi.org/10.1185/03007995.2012.748653.
24. Turnidge JD. 1998. The pharmacodynamics of β-lactams. Clin. Infect. Dis. 27:10-22. http://dx.doi.org/10.1086/514622.
25. Craig WA. 1995. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22:89-96. http://dx.doi.org/10.1016/0732-8893(95)00053-D.
26. Sader HS, Castanheira M, Flamm RK, Farrell DJ, Jones RN. 2014. Antimicrobial activity of ceftazidime-avibactam against Gramnegative organisms collected from U.S. medical centers in 2012. Antimicrob. Agents Chemother. 58: 1684-1692. http://dx.doi.org/10.1128/AAC.02429-13.
27. Castanheira M, Farrell SE, Krause KM, Jones RN, Sader HS. 2014. Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine United States census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrob. Agents Chemother. 58:833-838. http://dx.doi.org/10.1128/AAC.01896-13.
28. Borgonovi M, Merdjan H, Girard AM, Levasseur P, Quemin MH, Lowther J, Miossec C, Shlaes D, Drusano GL. 2008. Importance of NXL104 pharmacokinetics (PK) in the pharmacodynamics (PD) of ceftazadime+NXL104 combinations in an in vitro hollow fiber infection model, abstr A-023. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
29. Nichols P, Levasseur W, Li J, Das S. 2012. A threshold concentration of avibactam (AVI) during the pharmacokinetic decline phase, below which β-lactamase inhibition in Enterobacteriaceae becomes ineffective, abstr A-1760. Abstr. 52nd Intersci Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.